menu
    • menu
    [{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"OMERS Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Glecaprevir","moa":"||Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Enanta Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.20000000000000001,"dosageForm":"Tablet","sponsorNew":"Enanta Pharmaceuticals \/ OMERS Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Enanta Pharmaceuticals \/ OMERS Life Sciences"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Enanta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Glecaprevir","moa":"||Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AbbVie Inc \/ Enanta Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Enanta Pharmaceuticals"},{"orgOrder":0,"company":"CorMedix","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Public Offering","leadProduct":"Taurolidine","moa":"||Cell wall||Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Oncology","graph2":"Preclinical","graph3":"CorMedix","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"CorMedix \/ RBC Capital Markets","highestDevelopmentStatusID":"4","companyTruncated":"CorMedix \/ RBC Capital Markets"}]

    Find Clinical Drug Pipeline Developments & Deals for Pibrentasvir

    Menu

    Pibrentasvir

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AbbVie Inc

                            U.S.A
                            IFSCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glecaprevir,Pibrentasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Enanta Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Expands MAVYRET® Use for Hepatitis C for Enanta and AbbVie

                            Details : Mavyret (glecaprevir, pibrentasvir) inhibits P-glycoprotein, approved as the only eight-week treatment for three years and older with HCV infection without cirrhosis or with compensated cirrhosis.

                            Product Name : Mavyret

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 11, 2025

                            Lead Product(s) : Glecaprevir,Pibrentasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Enanta Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CorMedix

                            U.S.A arrow
                            IFSCC
                            Not Confirmed

                            CorMedix

                            U.S.A arrow
                            IFSCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taurolidine,Glecaprevir,Pibrentasvir

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : RBC Capital Markets

                            Deal Size : $85.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Cormedix Inc. Announces Pricing of Public Offering of Common Stock

                            Details : CorMedix intends to use the net proceeds for research and the development of product candidates, including Taurolidine for the treatment of neuroblastoma.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            June 27, 2025

                            Lead Product(s) : Taurolidine,Glecaprevir,Pibrentasvir

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : RBC Capital Markets

                            Deal Size : $85.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Enanta Pharmaceuticals

                            U.S.A arrow
                            IFSCC
                            Not Confirmed

                            Enanta Pharmaceuticals

                            U.S.A arrow
                            IFSCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glecaprevir,Pibrentasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : OMERS Life Sciences

                            Deal Size : $200.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.)...

                            Details : Through the divestment, Enanta will sale a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir) to OMERS Life Sciences. The net sale proceeds will be used to fund the continuing clinical development of virology p...

                            Product Name : Mavyret

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 25, 2023

                            Lead Product(s) : Glecaprevir,Pibrentasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : OMERS Life Sciences

                            Deal Size : $200.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth